BIOC - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the Biocept First Quarter Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded today, May 8, 2019. I would like to now turn the conference over to Ms. Kevin McCabe. Please go ahead.

Kevin McCabe

with McCabe Kevin is LHA. This thank Good conference participating today's for afternoon and call. in you

from Nall, Operations Joining Executive are Officer. Senior Biocept me Michael Chief and Kennedy, Officer; Edwin Commercial Vice Vice Financial President Officer; President Senior President Chief of and and Hendrick, Tim Chief and

During Private of Reform Securities statements this Act be the within of number management a will Litigation meaning call, XXXX. making forward-looking of the

terms will, can such statements all are historical be that could, identified generally intends, those predict, by the anticipate, Forward-looking plans, statements include of expects, as facts not believes, would, expect, potential, and negative terms. may, project, or should,

those Forward-looking statements. that uncertainties implied results, statements, and as forward-looking statements performance cause are risk, by to actual the unknown performance may known involve other or expressed factors from be or as or and well achievements that achievements different materially

see these X, update law, that of any time publicly or call about call. contains or risks, details obligation reflect information circumstances this Biocept as revise For today, events company's only please content occurred The that required to to SEC by this except as accurate after of information Filings. sensitive disclaims the any is XXXX, May

to like Michael Now, call Mike? the to I'd turn Nall. over

Michael Nall

to the a of the grew basis, in year. samples the we Thank our the first steps as quarter pleased year to our commercial samples half of sample to we second to off On you, report growth paying up took last as everyone and reinvigorate afternoon call Kevin sequentially received quarter last year-over-year compared of quarter XX% the good are on today. I'm fourth in XXXX the XXXX, XX% of XXXX. first from commercial

of biopsy test best our by And focusing segments various We historical our per grow we liquid that on technologies market test now be quarter. are of volume utilized. will continue where to can to volumes close anticipate the we peak

we that circulating renewed our our enables key our service tumor or pathology CTC call pathologists This base or add have participate the large practices including group These customer uro-oncology seen prostate the our shown And growth patient path In analyze quarter, markers cancer of to with our which cell to in ensuring A been about service manage partnership in expansion urology market. been Target on to MET. continuum. we and of Selector the driver mentioned local for customers the of and March, the also last able through our we predictive the and platform. called Target markers the the results these pleased LUGPAs. we proprietary including testing of thereby practices utility clinical the with that pathologists treatment. better into is our variant-X, hospital first in new CTC As able leverages a this year biomarkers, have patient growth interpret order the EmpowerTC, our critical tumors. are care to in expansion announced in to and Studies first EmpowerTC remain to unique Selector are additional testing, has AR quarter, launched enthusiastic the laboratories new offering solid PTEN to we in key contributor several this being prognostic several capability

based changes treatment. key patients for which our orders been blood has essays we've offerings, monitor to in clinicians Additionally, biomarkers as such undergoing PR and our cancer utilize increase by are seen in to an breast HERX need driven ER, for as the

targeting projects pipeline information Prognos of to companies that capture data with generated and is partnership with testing biopsy liquid from Prognos launch and this quarter monetize our is as to and this Our expected robust. the

diagnostics to continues therapies. may Prognos apply market order in billion help records over to and of companies and develop clinical laboratory targeted its laboratory pharmaceutical repository you XX Sciences Life to build to recall, artificial As intelligence

with with are revenue pleased then our collaborator Fisher hard pleased from Selector to announce expected diagnosed partner specific I'm the liquid as tumor the our have today to this launched first progresses. lung to we program their be and working with monitoring be panel in year of de-identified biopsy been working Thermo patients Prognos and commercialize with as Target Lung to for NGS first We've data our cancer. We test very and that a treatment position

the panel biotechnology targeted cancer and setting the lung this researchers marketing started in to and hospital to have pharmaceutical We physicians industries. in

supports multi-gene Thermo's and collaboration Our next specific to our commercialize with us access sequencing to panels. gives generation tumor Thermo technologies plan Scientific Fisher

panels we Middle technology first availability testing. Importantly, from additional this of that announced new research-use-only our market perform a tumor that begins Fisher our target other utilize research first Agiomix, of liquid the both build our We manufacturer Prognos collaboration kits commercial for with can circulating to we global content intended in announced services Biocept genomics and the sample. Biocept applications. Health. diagnostic share. and offerings, kit same liquid clinical the initiative our position support bioinformatics and international blood world around to our biopsy gene an the select and gain kits believe liquid Also, Africa as help to molecular laboratories with that biopsy the Asia single believe launch This provider quarter, a brand. company East, to in under to may We ctDNA we for or customer the helping and Thermo differentiation these enable data initiative us both market us DNA believe adoption and that only multi-gene We CTC that this has ctDNA biopsy with and with tested both all is analysis remains

protected detection is is for which our platform among biomarkers major Our are XX lung cancer. evaluated most Target and kit And in mutations, territories. patent high the EGFR United Selector in first oncogene sensitivity of for the frequently available States international

testing Mark our CE a year will applying the kit in the mark in and sometime for elsewhere We mark process CE if where world kit, technology recognized. is second in and oncogene reviewed planned a in article mutations three are inadequate. other We the EU highlights, we market of Europe. series additional of the the journal us published activating for this half featuring are granted a test biopsy anticipate The CE Biocept's when EGFR RUO this to And our in of in the the for obtaining case biopsy enable Clinics which peer quarter tissue Among mutations Selector in care testing first launch for medical EGFR patients in was liquid future. other Oncology. kits in highlighted detected the Target EGFR

all administer therapy the for support EGFR directed three to patients. to used were assays Our decision

patients at therapy, and complete approximately first detected a EGFR was after mutation response for The beginning had diagnosis the years. two patient

their became progressed. receive next disease with mutation And The patient's our eligible then AstraZeneca's EGFR the Upon treatment of detection patient's resistance two tested identified the blood generation assay to other the after both this TXXXM. Tagrisso. had was therapy, mutation,

We metastatic mutations. subtype the with resistance liquid biomarker breast also XXXX the novel cancer, detection cancer potential This has the biopsy predict receptor for for presented to treatment the poster a breast metastatic at majority present of patients for in ESRX positive Meeting patients. and assay hormone AACR Annual our response

New large company assay this a Investigator Kalinsky will happy to Kevin by Principal by conducted are University York. and study announce be at Dr. in pharmaceutical We in sponsored a included Columbia

in CTCs our and collaborated cancer. published work ability with ER with on Kalinsky Dr. have breast detect We to previously

designed enter our platform. announced the with used In certain leptomeningeal Providence determine and lung patients as as with LM provide utility a re-grow diagnosed test testing Studies the compared as from a future cord present tumor services leptomeningeal to of Health has Wayne the to liquid as and trial, and the are and Center will the for We use cerebral Target cancer, be continue patients to John's platform Results and cells evidence our clinical brain. biopsy confirming CSF occurred. data malignancies and the of medical our biopsy our add publications. such for or with to Saint liquid clinical reviewed metastases be occur Center if peer diagnosed or also within metastases of to John LM. to type of in products specimen supporting CSF when cancers the the initiation the In study in fluid of these Cancer spinal to meetings body this and diagnosis and standard validate will well with CSF methods spinal can breast Selector other

the The economic Target largest with testing annual may initiative one cancer is program the is patients. Turning actionable the Health, rate Blue of increase to monitoring National clinical We the today convention our biomarkers and Cross tested quality delivery in Summit the of cohort and goal diagnosed Shield are patients is of XXXX, interim advanced value of April lung molecular Allegheny healthcare improvement for XXX%, from systems designed to our in utility identified cancer this for is enrolled biopsy results Highmark integrated of Notably, treatable targeted and avoided initiative Blue that of our we Association. a in quality XX% second initiative so the qualify A in of key a Allegheny collaboration of biomarker evaluate tested testing Cross by show patients These the XX% therapies. utilizing lung Blue biomarkers the interim recall test. to Allegheny present in with with subsidiary for the its that not to still Pennsylvania. which profiling cancer at data to late an you far, Selector patients Health as national improvement many patients time. Blue the lung

enrollment results in larger from this advancing we're year patient could preliminary, later are XXXX. early completion in programs data these reported Clinical of or this goal. form XXX the While initiative towards a be

granted have of applications the I'm patent platform present, with covering patents in to XXXX, report patent several an XX that first Japan. we more additional At Finally, we pleased were CTC pending. our issued in globally, quarter

highly tumor rare field, with includes state processes access as idea entering partnership initiative agreements clinical additional include pathologist following. antibody by proprietary additional cell well publishing gaining with market case sensitive platform Allegheny Health our Fisher's micro assays. third kit summarize, pursue our party advancing the other our emerging in in of distribution capture, Our liquid quality priorities agreements quality additional Blue by Highmark patents cocktail generation next data Target the strategy contracts automating to new and with improvement CE new To plan by Selector's that technologies; channel laboratory into networks additional physicians; Prognos; our including backed integrated studies with collaboration health our biopsy Target and agreements use sequencing EmpowerTC and Selector panels, as Thermo the improve mark enrichment launching systems, obtaining specific for Increasing signing and penetration continuing results XXXX corporate signing traction our delivery for platform. patents System; our molecular our Cross and in margins; for and the healthcare with Europe; further through markets reproducibility, to our to from our monetizing testing gaining improve and productivity to the global validate hospital

our quarter. Tim? Now, first I'll Kennedy Tim results Tim turn afternoon and Kennedy the over the good to financial everyone. call to Mike for review Thanks,

XXXX, to in we up for excess expected XXXX In year. QX and respectively. in XXXX range billable and billable QX year-over-year. continue up of XX.X the the based The averaged approximately million in substantial XXXX, to is XX a the test billable from and of Revenues launch QX sequentially first XXX,XXX day in throughout revenues sales we mix to reimbursement average, QX reported XXX,XXX received accessions first fourth accessions XXXX. had on historical as to For in in QX versus XXXX. from XXX accessions XX% XX% quarter XXXX, accession QX compared samples XXXX $XXXX reported of X number in be Commercial new per and we were of XXXX the XX.X XXXX, continue also on billable increase the in of assays quarters

physician our strategy market new is volume on trends. the we in that and Our driving segments focused turnaround commercial specialties are believe

report XXXX, X.X of annualized the announcing the approximately revenue due The XXXX our in cash million QX reduce Turning last use happy same test usage our since of to we initiative was Cost in QX annualized in our began. of usage XXXX have in which million, revenue achieved baseline up cash that an reductions, basis year. an in higher cash on we're usage, the of cash QX of compared initiative this approximately to to related to X% volumes. increase primarily to XXXX X.X QX costs was compared in materials increase was period for cost when to to

XX% and components fixed begun with leverage revenue year-over-year the With revenue of the increased just cost we've once volume X%. of again to increasing costs increasing

primarily with QX to provide XXXX in and period growth last year-over-year share with XXXX to marketing trends same X.X the as accommodate development for per oncology operating X.X individual work expected automation loss a company panel. net assay validation development addition, million, or was QX volumes per continue improve. on costs XXXX, of to the share $X.XX to weighted the and Thermo was as The million X.X assays due X.X were of In expenses. our QX million new were This $X.XX year to QX and million as expenses or weighted first are X.X average General versus of quarter loss continue were XXXX The for in of million sales with on the we as shares laboratory to the X.X QX capacity shares and X.X average associated million compares continues million for million XXXX. quarter outstanding. expenses for reported expenses administrative the and XXXX molecular Fisher for to of compared net X.X compared to million Research X.X X.X higher million, first outstanding. contain XXXX increase for well

split we stock XXXX. of effective a a As was stock reminder conducted outstanding July reverse one-for-thirty in our which common

approximately XXXX. overview turn commercial manufacturer. previously our to million addition the in XX.X and as compared in approximately equivalents outsourcing Edwin an XX, on additional XXXX, to XX the reductions anticipate implementation automation, contract XXXX, our manufacturing over as March proceeds million Hendrick million usage we I'll of net a December of call totaled on Edwin? as X.X the of XX, X.X from three quarters realizing from cash million cash aggregate in well raised mentioned, Cash for of channel In coming reductions of the to the microfluidic use to progress. to in now cash date financings we

Edwin Hendrick

share hello to first that the I'm everyone. progress XXXX. several to make pleased and Tim in Thanks, we months of good continue

for when active to to not broader testing We market value gained Our platforms who patients remain for lung solid in the market biopsy call liquid momentum where is strategy our an adjunct use are tissue segments particularly focus tumors, efforts competitive have on the provide and biopsy with as for guidelines treatment biomarker unique of or advantages tissue pursue offer clinical clinical cancer, technology to cancer. feasible. treating as biopsy we where physicians our certain

based addition, and traction. commercial segments In integrated urology, team other is three and tumor oncology. our focused are market or These circulating differentiated on and have gained which CTC patented markets cell offerings breast are

and oncology expanded launch panel. prostate initiative target to in of NGS of predictive marker with launches, product very been see our Target of of and the integrated include the initiatives product in development launch line last our we've presence several EmpowerTC Selector of the quarter. breast includes first Lung which These impact months ARV-X, busy product the lastly, an started markets, the some over cancer and these arena, Within re-launch the our line, different recent urology the which we've the

advancing active expanded surveillance As undergo of the the mentioned, offering, low biomarkers Mike prostate enumeration and simply rate. for now with test or watchful their in to cancer is first announced diagnosed in testing Many launch at waiting prostate are if EmpowerTC increased includes cancer. and we men quarter, grade cancer CTC see prognostic which and our predictive an

our active are every back is surveillance phase monitor the exams. used typically customers months when biomarker input some to scheduled go to Our watchful is platform patients from in waiting that driven with for six patients our EmpowerTC can testing vision which their by of physician be

another cancer market testing enumeration also Our treatment contributing not marketplace. in cancers that breast select which EmpowerTC and many our significantly Several the CTC The of for services CTCs, but area disease capture breast the distinguishes growth only commercial these may have to CTCs, surgery our types resolve enabled renewed and in analysis volume and focus women. offerings an to your options of of of biomarkers is targets We good revenues. they enable focus on our the of believe is Biocept. test in Biocept

in unmet remain. medical However, there indications needs are breast several where major cancer

treatment. that we testing new in information selection. using arrested testing of breast assess monitoring that there the ongoing metastatic to providing breast believe with our for and liquid can doctors detection the treatment play to outreach we our Here role we tests began in highly cells cancer are relates our aid it in the important to breast diagnosed can found potential an circulating technology, biopsy disease community, interest growing XXXX as patients. biopsy and Since medical over liquid we And is tumor for patients In processed cancer. that with cancer CTCs

for options. remain triple benefit and or three instead to negative medical is of PR breast a potential biomarkers HERX, of positive indicates three major treatment targeted need markers unmet These radiation therapies that cancer from breast Additionally, cancer drug negative overexpression limited when chemotherapy. with the and ER major

and market sell with the through cancer At the allows Our United time to sales beginning any over as I placed if segment. physicians Center's. we integrative are play can lead of or for Board of of now doctors and these these patients known non-invasive want trained, Medical there's patients. FABNOs in growing known which major to support on physicians oncology can in year, role testing specific oncology reiterate of survivorship. potentially NDs, American academic options most treatment of for to over biomarkers with better to determine offering. help or medicine institutions XXXX their key Oncology, They're Naturopathic to more affiliated of the in changes, the integrated a focus many trained monitor and as to States, segment, our better resource part better practicing the Naturopathic diagnosis Fellows the naturopathic this care in cancer the naturopathic

Importantly, disease monitoring lies NDs Oncomine and Thermo we panels as for of the ctDNA a three specific well biopsy. liquid biopsy. your right seasoned allows the liquid to many or early could adopters flexibility the CTCs in NGS to Target it improved. are platforms our our recruited ctDNA for pleased panel, by Biocept, several using offer monitoring our offers technology and CTC evaluating choices also Selector Fisher's right sequencing different This selecting that report we and comes company offer When believe where tumor the that at is to when only launch patient important select us treatment is it supported promise biomarkers be that The real as now patient's tumor professionals. exciting time. next-gen informatics Lung very and the physician for joined target test as rep sequencing. I I'm Uniquely, has we sale per and backed And sales productivity experts

we Thank metric based territories the should be opportunities to continue currently and to over the further the per from and quarter samples that have time to force has that in determined per on fourth year mentioned Tim your sales trend in for believe turn team we're higher. see XXXX. attention expansion in of to just for the receiving solid of XX this field and back day quarter Mike. a the experienced of in I'll We growth. over that that previously, first sales day you place later As XXXX call have We and XX number with XX we increased the nearly

Michael Nall

Edwin. Thanks,

an effective select patients diagnosed best in to emerging a pathways with important cancer. physicians the with for cost innovate their invasive We and treatment to less broad help offering in of solutions field continue

performed assays our XX,XXX CTCs biomarker on as based information on leverage ctDNA. been samples both over differentiated have as platforms well proprietary are patient Our from and

Operator? property. And initiatives evidence on questions. focused drive we're leveraging opportunities overview, generate addition other that our We assays. the supports our that through specificity of and we take and high now continue to to strategic And growth, with organic efforts to ready sensitivity in investment clinical to in biomarker our are expanding intellectual partnerships by

Operator

now begin question-and-answer session. We will Instructions] [Operator the

Michael Nall

Conference corporate California. a waiting being I'll Micro question, that first at be in making to we're Air, like the mention presentation Bel While LD for held Ninth I'd Invitational

scheduled AM at on that's once at again. presentation to Our and is X, June take LD place XX Pacific the Micro

for that about first operator, the question. and ready Sorry I'm

Operator

no That's problem.

go comes Jason Maxim first McCarthy The from question group. with ahead. Please

Edwin Hendrick

Hello, Jason.

Jason McCarthy

Can cancer, Empower but where practices clinics what there's about about particular talked does you it's and guys. for taking how the breast prostate marketing growing for little perhaps this into segment segment, business? part questions. OBGYN talk of Hi, strategy had Thanks know the clinical more and about and of a a that fit segment, large previously the urology bit large urology the I cancer targeting you

Michael Nall

a urologist is office, as biopsy it's at Cancer the who care own the practices, be oncologist the user phases When I'll this ones group That's order mentioned provides. a point especially and then as they're of it's look into actually, working The that generally bit a lung be it's refer formed market a may he as standard namely And types. would that pass located becomes points but testing to with to blood we be be first in you or they great that's answer hospital generally, where involved whether most Jason, more it question. with of other medical but three a point cancer, or more lab. would that a and but they of the a call regional going and actually The liquid add decision oncologist Kind Blood lot of over today, numerous them America use they've Edwin Cancer the to liquid a it the our large have hospital biopsy and mega can information so segments, and information. you now would you tumor change. biopsy liquid of to it's And I'll largest patient type consolidated would generally pathologist going oncology or color, that still And surgical generally And OBGYN, they're validated know, breast medical biggest, then in are or breast - quickly find call more can of with little Jason. the over pathology going use out couple of in groups since Specialists Florida their it York and medical now between because more they early bought and US and in the generally ultimate the to a that's well practices. a systems the Tennessee. all up practices a New very in Oncology, OneOncology as are we're

And they have is to lab is us their of so servicing happens good and initiatives. that's located partners pathology may other they the to first own our hospitals on surgical and with be could needs the future for thing going testing the the be the buy But what offices. the focus lab pathologist oncology say, is practices then route all the the their to do our hospitals and system. they group And in

to in critical can a we them with and reimbursement interpretation only company liquid way participate testing. has that we're is this allow the that for the partner the them biopsy and So that's and

and folks So have the all on some that that's end I are think they the just we reimbursement do the of own. user critical to the over other their and advantage marketing which billing

that. NeoGenomics cancer think maybe also Edwin, same talk our kind been parts strategy how that other of negatives. about that growing model long-term in business win, with follow breast see proven namely, the we and them, business, you it's So the and have we more we fit can the people of we and monitoring through in right that it's

Edwin Hendrick

Sure.

do their focusing and their the pathology is hospital. laboratory out, to hospital. we order So what then we're that in biopsies is that work Mike professional from urology business pathologist of Breast on doing own to they most the side, want that have as those the on because as base lot pathology knowledge component their calling that through Mike large their cancer familiar they out, reason the typically truly Empower CTCs, so And a why the And oncology because can we're them pointed pointed pathology medical different. know much of get is offices site. with and we're through to groups own use on the do drive goes the through slightly

So truly that yet little the type Biocept of partnership the reading a from can on get offer. is testing local working everything's met they as the The through. coverage do and it local the pathologist, gets proprietary nice but national

So XX% kind change talked anywhere with to cancer with papers that attic some and especially those in do that breast There's thing out regards XX%. the over about negatives the that there three as state beautiful we triple markers are changes many change time. and of is there they between

and of regular draw So typically nailed want don't allows those any they positive this have radiation these on not our and them biomarkers, those patients on to options triple they're testing chemotherapy, these with a so for blood patients they and non-invasive negatives, basis. are other just any because really do to monitor

have a out to Tamoxifen of therapeutic. markers any not there radiation and and doses So find get that reduced Herceptin of least And then or them change, chemotherapy if get off that they true on them have there the or those called can or are drugs changed. at do out of they whether allow

because So all us exciting the breast is and of cancer out type already the that's of of this because marketplaces for monitoring driving of there the it's extremely data testing.

Jason McCarthy

considering them Fisher with you little Thermo perhaps NGS about could you other bit have got talk titles that perhaps bit developing Target partnership Fisher? with talk Thermo you're a launched. Can the about and already Lung you a potential the you little Selector Okay,

Michael Nall

Yeah. which we any more other the side and specific we'll that those made panels development haven't out the as on so coming there'll launch. some first and lung biopsy we're public centers here the ones, for the on for No, absolutely. options going in but other panel first about the then And quarter. partnering future. there's liquid giving for the with, but And you is with and statements them them on Yeah, recall, of solid we're be we're be one tumor the both information reimbursement in

Jason McCarthy

with go it well to be forward, Tim bit to you the looks in but view you increase question I all it is was guidance, back go the And revenue more Okay, in you you continuing? here. know - may like at the and you haven't you a you've the can this for place, XX% expect us this that a little revenue should company return quarter-over-quarter. pieces our I growth guess color capitalized on look Do put you where maybe as had given growth. give from trajectory

Tim Kennedy

yet Well, but Jason, can some modeling the detail remind where give you and you I more help probably Yeah. guidance, I'll give we just perhaps. little know with not point you, at Tim a we're bit

Jason McCarthy

Maybe historical session can and own make maybe assumptions. our from an we perspective

Tim Kennedy

Yeah, day progressed our sales continue are along, year per as the to increase. expect will that accessions we

quarter perspective. our to samples you a August As of in XX.X prepared the quarter progress went per to we XX quarter, quarter grow bit in first and a continued billable fourth et remarks, third mentioned quarter the hit through little on the we to in second in And this in cetera. vacations the seasonality sales But due is from third we our day hit of the expectation year. July as and

Jason McCarthy

have And impacted anticipate we the don't we Probes. now of being that the value FISH

Tim Kennedy

now the of urology $XXXX per that be, rate. had our rest we've Probes here so first we perspective first launched lower beginning progress a of as quarter launched accession at No, our that year. volume range revenue will the reimbursement net we to the the most so our Probes reimbursement the our in platform quarter, for that the back came FISH increase volume urology expect a in without in continue year, that we at that right, I from in of mentioned And as this of end FISH throughout urology

Jason McCarthy

Mike, can And about talk color. the a Prognos, with bit little little last so you bit a question, partnership more

generating be guidance, quantitate that could bioinformatics in you potentially of not from I'm this that mentioned XXXX. package sense it Prognos other You'd revenues how bioinformatics - from commercializing to would in a pharmacists market revenue that give what of or will you give groups look Not but to us already like? Can asking year interested? terms stream and

Michael Nall

that we ways with two marketing revenues them able and really will there's - it to be of part in gain Well, absolutely. initiative collaboration. from No, this Sure.

uploaded is now one our market into The it data of their and biomarkers database today. is first being

doing their further So database. is we're enriching what

previous with players of relationships to that Now, biopsy on the the side results they been it's they with in biggest have and that all space. liquid some have on tissue

company. so we're the biopsy first And liquid

we're way have And they that in total. EGFR therapies. So already companies certain excited pharma it testing have then about that. place The this example is for contracts in that EGFR works market data to targeted they

amount help we that of now that and enrich we'll a the share proportional to have that we database. input on based into get going So

in that think excited our get we term and longer much compared we share just that a go the identify I results that company, bit little customized see but small pharma projects, more specific managed got market existing smaller, deliver to is care. and protocol tissue the Prognos also this and that of area be that today to customized in I'm So things stream. could we'll on, that a that a would together where we've to pharma is working be Biocept we're place The share and between now interface a still target revenue will about that in now way there's if

in makes space. very us the some we now cost ball the was the our of very of valuable us well within a informatics it effective excited collaborations, big it players of that the be ability us was game, be so first to part initiative, game that - for potentially that could to as would way really the in that kind as a in we're it just and So as same fund, to of of different in value happy ball way this but two part have get the out gets the more

Jason McCarthy

So that package? last was point and could pharma, that essentially with you Prognos have bioinformatics customized like a the Biocept

Michael Nall

right. That's

Jason McCarthy

both end customer the require Then would the - on

Michael Nall

platform part And the fit. kind wouldn't sequencing Thermo be reported. we using them and leveraging I Fisher collaboration as view the from the pull It's nice their is that to that a Yeah. next-gen the that database data that we'll way of but the get relationship. we're necessarily with of generating pharma,

to go as So to technology technologies information provided, you of well the that the develop army trying able to without in achieve Prognos, pharma and see ability and as this that's and with having we between what of to ourselves we're with we've can And bioinformatics', probably that start providers, our our there and back managed to do the relation expensive vision very realm care monetize an the Biocept. is been hire exciting. not which of really are at the here to budget

Jason McCarthy

AI thermo into be uploaded used the platform, that the data Prognos to Then can correct? is the be second

Michael Nall

Yeah, that's right.

Jason McCarthy

Thank the Okay, guys. great. taking for you questions, all

Michael Nall

excellent. Sure,

Operator

would our for Instructions] Nall conference Michael question-and-answer over turn concludes the to This remarks. I [Operator like closing back any session. to

Michael Nall

look conference have participating I well, want we Great, quarter all on sharing for you call interest We our of day. thank for next report results. financial in a Biocept. call our when second and your today's our to forward and to progress Thanks great on

Operator

is today's Thank attending now you concluded. The for presentation. conference

disconnect. You may now

Biocept (BIOCQ) 8 May 192019 Q1 Earnings call transcript